Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06331455
Status:
RECRUITING
Last Update Posted:
2024-03-26
First Post:
2024-03-19
Brief Title:
Treatment of Pulmonary SUlcus Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation Immuno-oncology and Resection
Sponsor:
Marc de Perrot
Organization:
University Health Network Toronto
Study Overview
Official Title:
Treatment of Pulmonary SUlcus Pancoast and Chest Wall Non-small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SUPER
Brief Summary:
The SUPER trial is a prospective Phase II trial It is designed for patients with stage 2 or 3 non-small cell lung cancer NSCLC prior to surgery
Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation NORT and two cycles of Durvalumab an immunotherapy drug before their surgery
Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation NORT and two cycles of Durvalumab an immunotherapy drug before their surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None